PGZ Stock Overview
Provides specialty diagnostic services to consumer and practitioners in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.93 |
| 52 Week High | AU$1.17 |
| 52 Week Low | AU$0.66 |
| Beta | 0.73 |
| 11 Month Change | -12.74% |
| 3 Month Change | 12.80% |
| 1 Year Change | -17.41% |
| 33 Year Change | -70.16% |
| 5 Year Change | -51.32% |
| Change since IPO | -63.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| PGZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -1.9% | -1.8% |
| 1Y | -17.4% | 24.7% | 13.2% |
Return vs Industry: PGZ underperformed the German Healthcare industry which returned 26.3% over the past year.
Return vs Market: PGZ underperformed the German Market which returned 16.1% over the past year.
Price Volatility
| PGZ volatility | |
|---|---|
| PGZ Average Weekly Movement | 8.1% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PGZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PGZ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 6,994 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| PGZ fundamental statistics | |
|---|---|
| Market cap | €696.21m |
| Earnings (TTM) | -€384.73m |
| Revenue (TTM) | €1.06b |
0.7x
P/S Ratio-1.8x
P/E RatioIs PGZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGZ income statement (TTM) | |
|---|---|
| Revenue | AU$1.75b |
| Cost of Revenue | AU$1.21b |
| Gross Profit | AU$541.20m |
| Other Expenses | AU$1.18b |
| Earnings | -AU$636.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 30.99% |
| Net Profit Margin | -36.42% |
| Debt/Equity Ratio | 40.4% |
How did PGZ perform over the long term?
See historical performance and comparison